 Home > Active Ingredient News > Antitumor Therapy > JTO: Efficacy and safety of Rova-T combined with nivolumab or ipilimumab in the treatment of extensive-stage small cell lung cancer

JTO: Efficacy and safety of Rova-T combined with nivolumab or ipilimumab in the treatment of extensive-stage small cell lung cancer

 Last Update: 2021-03-19
 Source: Internet
 Author: User

Tags

msc stem cell

acoustic treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Delta-like protein 3 (DLL3) is a new type of target protein expressed in initial tumor cells, and more than 80% of small cell lung cancer patients will express this protein.

This study is an open phase I/II study to evaluate the safety and effectiveness of Rova-T in combination with nivolumab or ipilimumab for the previously treated extensive-stage small cell lung cancer (ES SCLC) .

To evaluate the safety and effectiveness of Rova-T combined with nivolumab or ipilimumab for the previously treated extensive-stage small cell lung cancer (ES SCLC).

Divided ES SCLC patients diagnosed by histology/cytology and previously treated (≥2 treatment options) into two groups.

Treatment time and duration of remission in the two groups

42 patients received treatment: 30 in the nivolumab group and 12 in the ipilimumab group.

All patients experienced one or more adverse events requiring emergency treatment (TEAE); 41 patients reported emergency adverse events deemed by the investigator to be related to the study drug

The most common TEAE is pleural effusion (n=20, 48%), and the most common grade 3 and above TEAE is anemia (n=9, 21%).

Optimal percentage change of target lesions in the two groups

The objective effective rate was 30% (12/40), of which the nivolumab group was 27.

Summary of efficacy

In summary, although the combination of Rova-T and nivolumab or ipilimumab can obtain good anti-tumor activity in previously treated ES SCLC patients, the dose level and administration evaluated by the patients in the study The program is not well tolerated .

Although the combination regimen of Rova-T and nivolumab or ipilimumab can obtain good anti-tumor activity in ES SCLC patients who have been previously treated, the dose level and dosing regimen evaluated in this study cannot be very good.

Original source:

Malhotra Jyoti, Nikolinakos Petros, Leal Ticiana et al.

org/10.
1016/j.
jtho.
2021.
02.
022">A Phase I / II Study of Rovalpituzumab Tesirine in Combination With Nivolumab ± Ipilimumab in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.